Adoptive immunotherapy for cancer: building on success Substantial progress has been made in our understanding of the molecular and cellular bases of T cell mediated anti-tumor responses. T cells are potent effectors of the adaptive anti-tumor immune response. Some target antigens recognized by tumor-reactive CD8+ T cells are non-mutated self-antigens that are also expressed by tumor cells. The molecular signals that modulate T cell activation, function and memory are being elucidated. Both positive and negative signals from co-stimulatory molecules have been shown to shape the anti-tumor response. Cytokines, including those with receptors that contain the common cytokine-receptor gamma chain have been shown to alter the programming of effector CD8+ T cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC010763-08
Application #
8763203
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
2013
Total Cost
$1,302,115
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Yang, Shicheng; Ji, Yun; Gattinoni, Luca et al. (2013) Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol Immunother 62:727-36
Hanada, Ken-ichi; Restifo, Nicholas P (2013) Double or nothing on cancer immunotherapy. Nat Biotechnol 31:33-4
Dudley, Mark E; Gross, Colin A; Somerville, Robert P T et al. (2013) Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 31:2152-9
Crompton, Joseph G; Rao, Mahendra; Restifo, Nicholas P (2013) Memoirs of a reincarnated T cell. Cell Stem Cell 12:6-8
Lugli, Enrico; Gattinoni, Luca; Roberto, Alessandra et al. (2013) Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. Nat Protoc 8:33-42
Zhang, L; Yu, Z; Muranski, P et al. (2013) Inhibition of TGF-? signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Ther 20:575-80
Dudda, Jan C; Salaun, Bruno; Ji, Yun et al. (2013) MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity 38:742-53
Gattinoni, Luca; Restifo, Nicholas P (2013) Moving T memory stem cells to the clinic. Blood 121:567-8
Kerkar, Sid P; Leonardi, Anthony J; van Panhuys, Nicolas et al. (2013) Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol Ther 21:1369-77
Morgan, Richard A; Chinnasamy, Nachimuthu; Abate-Daga, Daniel et al. (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36:133-51

Showing the most recent 10 out of 27 publications